{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T09:46:50Z","timestamp":1771667210663,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.jacl.2011.11.004","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T19:25:46Z","timestamp":1323285946000},"page":"235-243","source":"Crossref","is-referenced-by-count":12,"title":["Effects of coadministered extended-release niacin\/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia"],"prefix":"10.1016","volume":"6","author":[{"given":"Christie","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"Gleim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine McCrary","family":"Sisk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy O.","family":"Johnson-Levonas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yale","family":"Mitchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.11.004_bib1","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.11.004_bib2","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/01.CIR.97.18.1837","article-title":"Prediction of coronary heart disease using risk factor categories","volume":"97","author":"Wilson","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.11.004_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1001\/jama.284.3.311","article-title":"Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity","volume":"284","author":"Stamler","year":"2000","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2011.11.004_bib4","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S0021-9150(98)00219-6","article-title":"Triglycerides are more important in atherosclerosis than epidemiology has suggested","volume":"141","author":"Durrington","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2011.11.004_bib5","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.11.004_bib6","doi-asserted-by":"crossref","first-page":"7b","DOI":"10.1016\/S0002-9149(98)00031-9","article-title":"Hypertriglyceridemia as a cardiovascular risk factor","volume":"81","author":"Austin","year":"1998","journal-title":"Am J Cardiol"},{"issue":"Suppl M","key":"10.1016\/j.jacl.2011.11.004_bib7","first-page":"8","article-title":"The emergence of triglycerides as a significant independent risk factor in coronary artery disease","volume":"19","author":"Assmann","year":"1998","journal-title":"Eur. Heart J"},{"key":"10.1016\/j.jacl.2011.11.004_bib8","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1067\/mhj.2002.130301","article-title":"High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease","volume":"144","author":"Gotto","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2011.11.004_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9149(98)00448-2","article-title":"Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia","volume":"82","author":"Guyton","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.11.004_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2011.11.004_bib11","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.11.004_bib12","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.11.004_bib13","first-page":"229","article-title":"Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice","volume":"62","author":"Birjmohun","year":"2004","journal-title":"Neth. J. Med"},{"key":"10.1016\/j.jacl.2011.11.004_bib14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1472-6904-3-4","article-title":"The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]","volume":"3","author":"Mills","year":"2003","journal-title":"BMC Clin Pharmacol"},{"key":"10.1016\/j.jacl.2011.11.004_bib15","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2011.11.004_bib16","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacl.2011.11.004_bib17","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1021\/jm0603668","article-title":"Discovery of a potent and selective prostaglandin D(2) receptor antagonist, [(3R)-4-(4-Chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic Acid (MK-0524)","volume":"50","author":"Sturino","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.jacl.2011.11.004_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in dyslipidemic patients","volume":"101","author":"Paolini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.11.004_bib19","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.jacl.2011.11.004_bib20","first-page":"90","article-title":"Efficacy and safety profile of co-administered ER niacin\/laropiprant and simvastatin in dyslipidaemia","volume":"16","author":"Gleim","year":"2009","journal-title":"Br J Cardiol"},{"key":"10.1016\/j.jacl.2011.11.004_bib21","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0002-9149(03)00394-1","article-title":"Effects of extended-release niacin on lipoprotein subclass distribution","volume":"91","author":"Morgan","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.11.004_bib22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9149(01)01639-3","article-title":"Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia","volume":"88","author":"McKenney","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.11.004_bib23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/0002-8703(87)90636-3","article-title":"Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease","volume":"113","author":"Krauss","year":"1987","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2011.11.004_bib24","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/01.CIR.88.6.2762","article-title":"Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events","volume":"88","author":"Phillips","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.11.004_bib25","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1161\/01.CIR.102.10.1082","article-title":"Lipoprotein(a) and coronary artery disease. Meta-analysis of prospective studies","volume":"102","author":"Danesh","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.11.004_bib26","unstructured":"NIH stops clinical trial on combination cholesterol treatment: Lack of efficacy in reducing cardiovascular events prompts decision. National Institute of Health News 2011. Available at: http:\/\/www.nih.gov\/news\/health\/may2011\/nhlbi-26.htm. Accessed October 27, 2011."},{"key":"10.1016\/j.jacl.2011.11.004_bib27","unstructured":"HPS-2 THRIVE Web site. Available at: http:\/\/www.ctsu.ox.ac.uk\/\u223cthrive\/. Accessed November 18, 2010."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411008269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411008269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T10:23:42Z","timestamp":1561026222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411008269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1933287411008269"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.11.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}